title: A Comparative Study of Intravenous Injection Form and Oral Jelly Form of Alendronate Sodium Hydrate for Bone Mineral Disorder after Gastrectomy.
abstract: OBJECTIVE
  Osteoporosis is found to have high prevalence after gastrectomy and therefore, it is important to prevent this condition by means of effective medication, such as alendronate sodium hydrate.
  
  
  METHODS
  A total number of 48 gastric cancer patients diagnosed with osteoporosis after R0 gastrectomy was registered in this study between December 2013 and August 2014. Twenty-three patients received intravenous (i.v.) alendronate sodium hydrate and 25 patients received the drug in an oral jelly form. Serological and urinary examinations related to bone metabolism and bone mineral density (BMD) were performed periodically and the results obtained from the 2 groups were compared.
  
  
  RESULTS
  BMD increased, serum levels of bone-specific alkaline phosphatase and tartrate-resistant acid phosphatase-5b, and the urine level of urine N-terminal telopeptide decreased with time in both groups. However, the serum Ca level did not change. Two-way analysis of variance revealed no significant differences in these factors between the 2 groups.
  
  
  CONCLUSIONS
  It is essential to prevent both forms of osteoporosis by using alendronate sodium hydrate after gastrectomy for gastric cancer. A prospective, randomized, controlled trial in many patients following long duration should be conducted to clarify the benefits of i.v. alendronate sodium hydrate.
authors.affiliation: Department of Surgery, Gastroenterological Center, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
authors.forename: Chikara
authors.initials: C
authors.lastname: Kunisaki
authors.forename: Yusaku
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Takashi
authors.initials: T
authors.lastname: Kosaka
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Miyamoto
authors.forename: Sho
authors.initials: S
authors.lastname: Sato
authors.forename: Hideaki
authors.initials: H
authors.lastname: Suematsu
authors.forename: Norio
authors.initials: N
authors.lastname: Yukawa
authors.forename: Kei
authors.initials: K
authors.lastname: Sato
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Izumisawa
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Akiyama
authors.forename: Masataka
authors.initials: M
authors.lastname: Taguri
authors.forename: Takeharu
authors.initials: T
authors.lastname: Yamanaka
authors.forename: Itaru
authors.initials: I
authors.lastname: Endo
mesh_terms: D000284:Administration, Oral; D000368:Aged; D019386:Alendronate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000469:Alkaline Phosphatase / Q000097:blood; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002118:Calcium / Q000097:blood; D024042:Collagen Type I / Q000652:urine; D005260:Female; D005743:Gastrectomy / Q000009:adverse effects*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D010455:Peptides / Q000652:urine; D011446:Prospective Studies; D013274:Stomach Neoplasms / Q000601:surgery*; D000071681:Tartrate-Resistant Acid Phosphatase / Q000097:blood
chemical_list: D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D000469:Alkaline Phosphatase; C000605510:ACP5 protein, human; D000071681:Tartrate-Resistant Acid Phosphatase; D002118:Calcium; D019386:Alendronate